Mucosolvan in the treatment of patients with primary Sjögren's syndrome. Results from a double-blind cross-over investigation.
Thirty-six patients with primary Sjögren's syndrome were randomized to Mucosolvan (60 mg X 2 daily) or placebo, in a double-blind cross-over study. Each period of treatment was 3 weeks with 1 week wash-out in between. None of the objective ophthalmological tests (Schirmer-1-test, break-up time, van Bijsterveld score, cornea sensitivity, appearance of nuclear chromatin in conjunctival epithelial cells, tear lysozyme) improved during the investigation period.